The Vanguard Group, Inc. recently announced the acquisition of new stake in P10 Inc (NYSE:PX). The institutional investor has increased its shareholding in the Financial company by 0.70% to 3.96 million shares with purchase of 27437.0 shares. This fresh investment now brings its stake to 7.46% valued currently at $40.42 million. In addition, BlackRock Fund Advisors raised its holdings by 68657.0 to 1.95 million shares. And Grandeur Peak Global Advisors LLC has lifted its position by 1.32% or 20080.0 shares – to 1.54 million shares.
With over 0.49 million P10 Inc (PX) shares trading Friday and a closing price of $9.78 on the day, the dollar volume was approximately $4.76 million. The shares have shown a negative half year performance of -9.36% and its price on 12/22/23 gained nearly 0.93%. Currently, there are 42.37M common shares owned by the public and among those 41.27M shares have been available to trade.
Insiders at the company have transacted a total of 40 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 17 of these insider trades were purchases, accounting for 1,528,665 shares. Insider sales of the common stock occurred on 23 occasions, with total insider shares sold totaling 658,884 shares.
The top 3 mutual fund holders in P10 Inc are Federated Hermes Kaufmann Small C, T Rowe Price Small Cap Stock Fund, and AB Small Cap Growth Portfolio. Federated Hermes Kaufmann Small C owns 3.18 million shares of the company’s stock, all valued at over $32.46 million. T Rowe Price Small Cap Stock Fund sold 3000.0 shares to see its total holdings shrink to 1.98 million shares valued at over $20.18 million and representing 3.73% of the shares outstanding. AB Small Cap Growth Portfolio sold 27002.0 shares to bring its total holdings to over 1.46 million shares at a value of $14.91 million. AB Small Cap Growth Portfolio now owns shares totaling to 2.75% of the shares outstanding.
Shares of P10 Inc (NYSE: PX) opened at $9.67, down -$0.02 from a prior closing price of $9.69. However, the script later moved the day high at 9.81, up 0.93%. The company’s stock has a 5-day price change of -4.12% and -15.18% over the past three months. PX shares are trading -8.34% year to date (YTD), with the 12-month market performance down to -3.93% lower. It has a 12-month low price of $8.75 and touched a high of $13.41 over the same period. PX has an average intraday trading volume of 340.44K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -1.02%, 0.64%, and -8.14% respectively.
Institutional ownership of P10 Inc (NYSE: PX) shares accounts for 27.24% of the company’s 42.37M shares outstanding. Mutual fund holders own 22.11%, while other institutional holders and individual stakeholders account for 38.98% and 21.07% respectively.
It has a market capitalization of $1.14B and a beta (3y monthly) value of 0.90. The earnings-per-share (ttm) stands at -$0.02. The company has a debt-to-equity ratio at 0.73. Price movements for the stock have been influenced by the stock’s volatility, which stands at 3.59% over the week and 2.92% over the month.
The lowest estimate earnings-per-share for the quarter is $0 while analysts give the company a high EPS estimate of $0. Earnings per share for the fiscal year are expected to increase by 2.97%, and 15.00% over the next financial year. EPS should shrink at an annualized rate of 14.40% over the next five years, compared to 49.36% over the past 5-year period.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 7 brokerage firm advisors rate P10 Inc (PX) as a “Strong Buy” at a consensus score of 1.14. Specifically, 6 Wall Street analysts polled rate the stock as a buy, while 0 of the 7 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the PX, a number of firms have released research notes about the stock. Barclays stated their Overweight rating for the stock in a research note on August 31, 2022, with the firm’s price target at $15.
